COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

NCT06168032 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

1224

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Recurrent
Lung Cancer
Vaccination
Antibody
Chemotherapy
Immune Checkpoint Inhibitor

Interventions

BIOLOGICAL: Any Chinese government-recommended COVID-19 booster vaccine

Sponsor

Peking Union Medical College Hospital